Document is current
Any future updates will be listed below
-
Authors
Kwon, Jason J.
Hajian, Behnoush
Bian, Yuemin https://orcid.org/0000-0002-5845-772X
Young, Lucy C.
Amor, Alvaro J.
Fuller, James R. https://orcid.org/0000-0002-9029-0923
Fraley, Cara V.
Sykes, Abbey M.
So, Jonathan
Pan, Joshua
Baker, Laura
Lee, Sun Joo
Wheeler, Douglas B.
Mayhew, David L.
Persky, Nicole S.
Yang, Xiaoping https://orcid.org/0000-0002-6811-4915
Root, David E. https://orcid.org/0000-0001-5122-861X
Barsotti, Anthony M.
Stamford, Andrew W.
Perry, Charles K.
Burgin, Alex
McCormick, Frank https://orcid.org/0000-0002-6619-7120
Lemke, Christopher T.
Hahn, William C. https://orcid.org/0000-0003-2840-9791
Aguirre, Andrew J. https://orcid.org/0000-0002-0701-6203
- License Information
-
More Information
Article History
Received: 13 January 2022
Accepted: 2 June 2022
First Online: 13 July 2022
Competing interests
: D.E.R. receives research funding from members of the Functional Genomics Consortium (Abbvie, BMS, Jannsen, Merck and Vir), and is a director of Addgene. D.L.M. consults for the legal consulting firm Shook, Hardy & Bacon. F.M. is a consultant for the following companies: Amgen, Daiichi, Frontiers Med, Exuma Biotech, Ideaya Biosciences, Kura Oncology, Leidos Biomedical Research, PellePharm, Pfizer, PMV Pharma and Quanta Therapeutics. F.M. is a consultant for and cofounder of the following companies (with ownership interest including stock options): BridgeBio; DNAtrix, Olema Pharmaceuticals and Quartz. F.M. is the scientific director of the National Cancer Institute RAS Initiative at the Frederick National Laboratory for Cancer Research–Leidos Biomedical Research. F.M. has been a recipient of research grants from Daiichi Sankyo and Gilead Sciences and has a current grant from Boehringer Ingelheim. W.C.H. is a consultant for Thermo Fisher Scientific, Solasta Ventures, MPM Capital, KSQ Therapeutics, Tyra Biosciences, Jubilant Therapeutics, Function Oncology, RAPPTA Therapeutics, Frontier Medicine and Calyx. A.J.A. has consulted for Oncorus, Arrakis Therapeutics, Syros Pharmaceuticals, Boehringer Ingelheim, T-knife Therapeutics, AstraZeneca, Mirati Therapeutics and Merck, and has research funding from Mirati Therapeutics, Syros Pharmaceuticals, Bristol Myers Squibb, Revolution Medicines, Novartis and Novo Ventures that is unrelated to this work. W.C.H. and A.J.A. have funding from Deerfield that is related to the work described here.
